Ronald Prussick, MD
Dermatology · N Bethesda, MDNPI 1588647085
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $515,211 of the $619,975 with a category attached, or 83.1%. 31 manufacturers reported payments, led by AbbVie at 41.8% of the total. Reporting peaked in 2019 at $161,551 and has fallen 50.6% since, to $79,746 in 2025. Among dermatology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 906 payments — averaging $684.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$259K
- Janssen Scientific Affairs, LLC$139K
- Johnson & Johnson$86K
- Amgen$50K
- Dermavant Sciences, Inc.$27K
- UCB, Inc.$19K
- plus $39K from 25 others
Across 2 payments — averaging $19,035 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$28K
- Amgen$10K
What the payments were for
- Consulting fees$39,5106%
- Speaking & faculty fees$515,21183%
- Travel & lodging$47,0888%
- Food & beverage$17,5723%
- Education$5930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 268 | $259,054 |
| Janssen Scientific Affairs, LLC | 95 | $138,751 |
| Johnson & Johnson(2 entities) | 112 | $86,365 |
| Amgen | 46 | $50,122 |
| Dermavant Sciences, Inc. | 68 | $27,085 |
| UCB, Inc. | 42 | $19,488 |
| Bristol Myers Squibb | 28 | $17,086 |
| Pfizer | 18 | $5,821 |
| Organon | 3 | $4,349 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,990 |
| Sun Pharmaceutical Industries Inc. | 15 | $3,559 |
| Novartis | 71 | $1,125 |
| Lilly USA, LLC | 40 | $595 |
| Incyte Corporation | 20 | $526 |
| Sanofi | 12 | $431 |
| E.r. Squibb & Sons, L.L.C. | 12 | $291 |
| Galderma Laboratories, L.p. | 8 | $267 |
| Arcutis Biotherapeutics, Inc. | 8 | $210 |
| Regeneron Healthcare Solutions, Inc. | 6 | $178 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $137 |
| LEO Pharma Inc. | 4 | $97 |
| Almirall LLC | 4 | $80 |
| EPI Health, LLC | 4 | $78 |
| Mayne Pharma Commercial LLC | 3 | $68 |
| Revance Therapeutics, Inc. | 1 | $56 |
| Boehringer Ingelheim | 2 | $52 |
| Biofrontera Inc. | 3 | $40 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Sandoz | 1 | $19 |
| Strata Skin Sciences, Inc. | 2 | $19 |
| Botanix SB Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$619,975 in reported general payments places this provider in the 95th percentile of 306 dermatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 18 | $104,577 |
| VtamaTapinarof | 12 | $16,294 |
| ZoryveRoflumilast | 11 | $9,123 |
| Pimecrolimus | 26 | $6,772 |
| Tacrolimus | 12 | $5,928 |
| Ivermectin | 12 | $2,446 |
| Fluorouracil | 36 | $2,348 |
| Clobetasol Propionate | 23 | $1,773 |
| Triamcinolone Acetonide | 129 | $1,682 |
| Metronidazole | 35 | $1,543 |
| Ketoconazole | 75 | $1,372 |
| Clindamycin Phosphate | 22 | $676 |
| Doxycycline Monohydrate | 17 | $472 |
| Mometasone Furoate | 22 | $437 |
| Mupirocin | 34 | $295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $50,122 | $104,57718 claims |
| Dermavant Sciences, Inc.Vtama | $27,085 | $16,29412 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $210 | $9,12311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 306 dermatology providers in Maryland.
Other dermatology in N Bethesda
- Benjamin LockshinSilver Spring$4M
- Shawn KwatraBaltimore$1.1M
- Chesahna Kindred WeaverMarriottsville$837K
- Oanh LauringNottingham$763K
- Rebecca KazinChevy Chase$342K
- Susan WalkerBethesda$221K
- Monte MeltzerBerlin$220K
- Valerie CallenderGlenn Dale$183K
- David StrobelCatonsville$180K
- Natalia BilesMillersville$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.